Treatment and outcomes in adolescents with schizophrenia

Journal of Clinical Psychiatry

Volumn 59, Issue SUPPL. 1, 1998, Pages 50-56

  Schulz, S Charles ^a   Findling, Robert L ^a   Friedman, Lee ^a   Kenny, John T ^a   Wise, Alexandria L ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; LOXAPINE; LOXAPINE SUCCINATE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; THIORIDAZINE; TIOTIXENE; ZIPRASIDONE;

ADOLESCENT; CLINICAL TRIAL; EXTRAPYRAMIDAL SYMPTOM; FOLLOW UP; HUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REVIEW; SCHIZOPHRENIA; SEDATION; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

EID: 0031933685     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Loranger AW. Sex difference in age of onset of schizophrenia. Arch Gen Psychiatry 1984;41:157-161
2. Elkis H, Friedman L, Wise A, et al. Meta-analyses of studies of ventricular enlargement or cortical sulcal prominence in mood disorders: comparison with controls or schizophrenia. Arch Gen Psychiatry 1995;52:1-12
3. Findling RL, Friedman L, Kenny JT, et al. Adolescent schizophrenia: a methodologic review of the current neuroimaging and neuropsychologic literature. J Autism Dev Disord 1995;25(6):627-639
4. Schulz SC, Koller MM, Kishore PR, et al. Ventricular enlargement in teenage patients with schizophrenia spectrum disorder. Am J Psychiatry 1983; 140:1592-1595
5. Friedman L, Findling RL, Buck J, et al. Structural MRI and neuropsychological assessments in adolescent patients with either schizophrenia or affective disorders. Schizophr Res 1996;18:189-190
6. Ward KE, Friedman L, Wise A, et al. Meta-analysis of brain and cranial size in schizophrenia. Schizophr Res 1996;22:197-213
7. Jacobsen LK, Giedd JN, Vaituzis AC, et al. Temporal lobe morphology in childhood-onset schizophrenia. Am J Psychiatry 1996;153:355-361
8. Frazier JA, Giedd JN, Hamburger SD, et al. Brain anatomic magnetic resonance imaging in childhood-onset schizophrenia. Arch Gen Psychiatry 1996;53:617-624
9. Goldberg TE, Karson CN, Leleszi JP, et al. Intellectual impairment in adolescent psychosis: a controlled psychometric study. Schizophr Res 1988;1: 261-266
10. Kenny JT, Friedman L, Cola D, et al. Neuropsychological impairments in adolescent schizophrenics [abstract]. Presented at the Annual Meeting of the Society of Biological Psychiatry; May 19-21, 1994; Philadelphia, Pa
11. Hagger C, Buckley P, Kenny JT, et al. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993;34:702-712
12. Jones P, Rogers B, Murray R, et al. Child developmental risk factors for adult schizophrenia in British 1946 birth cohort. Lancet 1994;344: 1398-1402
13. McNeil TF, Cantor-Graae E, Nordstrom LG, et al. Head circumference in "preschizophrenic" and control neonates. Br J Psychiatry 1993;162: 517-523
14. Findling RL, Grcevich SJ, Lopez I, et al. Antipsychotic medications in children and adolescents. J Clin Psychiatry 1996;57(suppl 9):19-23
15. Englehardt DM, Polizos P, Waizer J, et al. A double-blind comparison of fluphenazine and haloperidol in outpatient schizophrenic children. J Autism Child Schizophr 1973;3:128-137
16. Spencer EK, Kafantaris V, Padron-Gayol MV, et al. Haloperidol in schizophrenic children: early findings from a study in progress. Psychopharmacol Bull 1992;28:183-186
17. Pool D, Bloom W, Mielke DH, et al. A controlled evaluation of Loxitane in seventy-five adolescent schizophrenic patients. Curr Ther Res Clin Exp 1976;19:99-104
18. Realmuto GM, Erickson WD, Yellin AM, et al. Clinical comparison of thiothixene and thioridazine in schizophrenic adolescents. Am J Psychiatry 1984;141:440-442
19. Schulz SC, Koller MM. Schizophrenia and schizophreniform disorder. In: Hsu LKG, Hersen M, eds. Recent Developments in Adolescent Psychiatry. New York, NY: John Wiley & Sons; 1989:289-308
20. Keepers GA, Clappison VJ, Casey DE: Initial anticholinergic prophylaxis for neuroleptic-induced syndrome. Arch Gen Psychiatry 1983;40: 1113-1117
21. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment resistant schizophrenic. Arch Gen Psychiatry 1988;45:789-796
22. Birmher B, Baker R, Kapur S, et al. Clozapine for the treatment of adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 1992;31: 160-164
23. Remschmidt H, Schulz E, Martin PDM. An open trial of clozapine in thirty-six adolescents with schizophrenia. J Child Adolesc Psychopharmacol 1994;4:31-41
24. Kumra S, Frazier JA, Jacobsen LK, et al. Childhood-onset schizophrenia: a double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 1996;53;1090-1097
25. Quintana H, Keshavan M. Risperidone in children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 1995;34:1292-1296
26. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835
27. Simeon JG, Carrey NJ, Wiggins DM, et al. Risperidone effects in treatment-resistant adolescents: preliminary case reports. J Child Adolesc Psychopharmacol 1995;5:69-79
28. Grcevich SJ, Findling, RL, Rowane WA, et al. Risperidone in the treatment of children and adolescents with schizophrenia: a retrospective study. J Child Adolesc Psychopharmacol 1996;6:251-257
29. Kolakowski T, Williams AO, Ardern M, et al. Schizophrenia with good and poor outcome, I: early clinical features, response to neuroleptics and signs of organic dysfunction. Br J Psychiatry 1985;146:229-246
30. Welner A, Welner Z, Fishman R. Psychiatric adolescent inpatients: eight-to-ten-year follow-up. Arch Gen Psychiatry 1979;36:698-700
31. Krauss M, Muller-Thomsen T. Schizophrenia with onset in adolescence: an 11-year follow up. Schizophr Bull 1993;19(4):831-841
32. Davis JM, Schaffer CB, Killian GA, et al. Important issues in the drug treatment of schizophrenia. Schizophr Bull 1980(special report);109-126
33. Johnstone EC, Crow TJ, Johnson AL, et al. The Northwick Park study of first episodes of schizophrenia, I: presentation of the illness and problems relating to admission. Br J Psychiatry 1986;148:115-120
34. May PRA, Tuma AH, Dixon WJ. Schizophrenia: a follow-up study of results of treatments, I: design and other problems. Arch Gen Psychiatry 1976;33:474-480
35. Loebel AD, Lieberman JA, Alvir JMJ, et al. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992;149:1183-1188